1. McCarthy, D.M. and R.T. Jensen, Zollinger-Ellison syndrome:current issues. 1985: p. 25.

2. Passaro, E., Jr., T.J. Howard, M.P. Sawicki, P.C. Watt, and B.E. Stabile, The origin of sporadic gastrinomas within the gastrinoma triangle: a theory. Arch Surg, 1998. 133(1): p. 13-6; discussion 17.

3. Debas, H.T., P. Soon-Shiong, A.D. McKenzie, et al., Use of secretin in the roentgenologic and biochemical diagnosis of duodenal gastrinoma. Am J Surg, 1983. 145: p. 408.

4. Thompson, N., A. Vinik, and F. Eckhauser, Microgastrinomas of the duodenum. A cause of failed operations for the Zollinger-Ellison syndrome. Ann Surg, 1989. 209: p. 396-404.

5. Norton, J.A., J.L. Doppman, and R.T. Jensen, Curative resection in Zollinger-Ellison sydrome. Ann Surg, 1992. 215: p. 8.

6. Sugg, S.L., J.A. Norton, D.L. Fraker, et al., A prospective study of intraoperative methods to diagnose and resect duodenal gastrinomas. Ann Surg, 1993. 218: p. 138.

7. Bhagavan, B.S., R.E. Slavin, J. Goldberg, and R.N. Rao, Ectopic gastrinoma and Zollinger-Ellison syndrome. Hum Pathol, 1986. 17: p. 584-592.

8. Fox, P.S., J.W. Hofmann, J.J. DeCosse, and S.D. Wilson, The influence of total gastrectomy on survival in malignant Zollinger-Ellison tumors. Ann Surg, 1974. 180: p. 558.

9. Friesen, S.R., R.E. Bolinger, A.P. GE, and J.E. McGuigan, Serum gastrin levels in malignant Zollinger-Ellison syndrome after total gastrectomy and hypophysectomy. Ann Surg, 1970. 172: p. 504.

10. Sircus, W., Vagotomy in Z-E syndrome. Gastroenterology, 1979. 79(607).

11. Stabile, B.E. and J. E. Passoro, Benign and malignant gastrinoma. Am J Surg, 1985. 148: p. 144.

12. Wolfe, M.M., R.W. Alexander, and J.E. McGuigan, Extrapancreatic, extraintestinal gastrinoma. N Engl J Med, 1982. 306: p. 1533.

13. Zollinger, R.M., Gastrinoma: factors incluencing prognosis. Surgery, 1985. 97: p. 49.

14. Herrmann, M.E., M.C. Ciesla, G. Chejfec, S.A. DeJong, and S.L. Yong, Primary nodal gastrinomas. Arch Pathol Lab Med, 2000. 124(6): p. 832-5.

15. Wu, P.C., H.R. Alexander, D.L. Bartlett, J.L. Doppman, D.L. Fraker, J.A. Norton, F. Gibril, F. Fogt, and R.T. Jensen, A prospective analysis of the frequency, location, and curability of ectopic (nonpancreaticoduodenal, nonnodal) gastrinoma. Surgery, 1997. 122(6): p. 1176-82.

16. Norton, J.A., H.R. Alexander, D.L. Fraker, D.J. Venzon, F. Gibril, and R.T. Jensen, Possible primary lymph node gastrinoma: occurrence, natural history, and predictive factors: a prospective study. Annals of Surgery, 2003. 237(5): p. 650-9.

17. Deveney, C.W., K.S. Deveney, D. Stark, et al., Resection of gastrinomas. Ann Surg, 1983. 198: p. 546.

18. Friesen, S.R., The development of endocrinopathies in the prospective screening of two families with MEA-I. World J Surg, 1979. 3: p. 753.

19. Lamers, C.B., J.T. Buis, and J.H.V. Tongeren, Secretin-stimulated serum gastrin levels in hyperparathyroid patients from families with multiple endocrine adenomatosis-type 1. Ann Intern Med, 1977. 86: p. 719.

20. Malagelada, J.R., A.J. Edis, M.A. Adson, J.A. van Heerden, and V.L. Go, Medical and surgical options in the management of patients with gastrinoma. Gastroenterology, 1983. 84: p. 1524.

21. Mignon, M., P. Ruszniewski, S. Haffar, et al., Current approach to the management of tumoral process in patients with gastrinoma. World J Surg, 1986. 10: p. 703.

22. Thompson, N.W., R.V. Lloyd, R.H. Nishiyama, et. al., MEN 1 pancreas: a histological and immunohistochemical study. World J Surg, 1984. 8: p. 561.

23. Friesen, S.R., Update on the diagnosis and treatment of rare neuroendocrine tumors. Surg Clin North Am, 1987. 67: p. 379.

24. Vinik, A.I., W.E. Strodel, K.J. Cho, F.E. Eckhauser, and N.W. Thompson, Localization of hormonally active gastrointestinal tumors.In Endocrine Surgery Update, Edited by N.W. Thompson, A. I. Vinik. 1983, New York: Grune & Stratton.

25. Landor, J., Control of the Zollinger-Ellison syndrome by excision of primary and metastatic tumor. Am J Surg, 1984. 147: p. 406.

26. Stabile, B.E., D.J. Morrow, and J. E. Passoro, The gastrinoma triangle: operative implications. Am J Surg, 1984. 147: p. 25.

27. Chen, Y.J., A. Vortmeyer, Z. Zhuang, S. Huang, and R.T. Jensen, Loss of heterozygosity of chromosome 1q in gastrinomas: occurrence and prognostic significance. Cancer Res, 2003. 63(4): p. 817-23.

28. Diaz-Rubio, J.L., A. Duarte-Rojo, M. Saqui-Salces, A. Gamboa-Dominguez, and G. Robles-Diaz, Cellular proliferative fraction measured with topoisomerase II alpha predicts malignancy in endocrine pancreatic tumors. Arch Pathol Lab Med, 2004. 128(4): p. 426-9.

29. Ellison, E.C., L.C. Carey, J. Sparks, et. al., Early surgical treatment of gastrinoma. Am J Med, 1987. 82: p. 17.

30. Weber, H.C., D.J. Venzon, R.T. Jensen, and D.C. Metz, Studies on the interrelation between Zollinger-Ellison syndrome, Helicobacter pylori, and proton pump inhibitor therapy. Gastroenterology, 1997. 112(1): p. 84-91.

31. Kothary, P.C., P.J. Fabri, and e.a. W. Gower, Evaluation of nh2-terminus gastrins in gastrinoma syndrome. J Clin Endocrinol Metab, 1986. 62: p. 970-974.

32. Vinik, A.I., W.E. Stordel, and T.M. O'Dorisio, Endocrine tumors of the gastroenteropancreatic axis. Diagnosis and Management of Endocrine-Related Tumors. Edited by R. Santen and A. Manni. 1984, Boston: Martinus Nijhoff. p. 305.

33. Betts, J.B., B.P. O'Malley, and F.D. Rosenthal, Hyperparathyroidism: a prerequisite for Zollinger-Ellison syndrome in MEA-I: report of a further family and a review of the literature. Q J Med, 1980. 49: p. 69.

34. Friesen, S., Treatment of Zollinger-Ellison syndrome: a 25-year assessment. Am J Surg, 1982. 143: p. 331.

35. Dunnick, N.R., J.L. Doppman, S. Mills, and D. McCarthy, Computed tomographic appearance of non-beta (or non-insulin producing) pancreatic islet cell tumors. Radiology, 1980. 135: p. 117.

36. Cho, K.J., A. Vinik, N.W. Thompson, et. al., Localization of the source of hyperinsulinism: percutaneous transhepatic portal and pancreatic vein catherization with hormone asssay. Am J Roentgenol, 1982. 139: p. 237-245.

37. Ingemansson, S., L.I. Larsson, and F. Stadil, Pancreatic vein catheterization with gastrin assay in normal patients and patients with Zollinger-Ellison syndrome. Am J Surg, 1977. 134: p. 558.

38. Rosch, T., C.J. Lightdale, J.F. Botet, et al., Localization of pancreatic endocrine tumors by endoscopic ultrasonography. N Engl J Med, 1992. 326: p. 1721.

39. Zimmer, T., K. Ziegler, R.M. Liehr, and et al., Endosonography of neuroendocrine tumors of the stomach, duodenum, and pancreas. Ann N Y Acad Sci, 1994. 733: p. 425.

40. Norton, J.A., Doppman J.L., Collen M.J. et. al. Prospective study of gastrinoma localization and resection in patients with Zollinger-Ellison syndrome. Ann Surg, 1986. 204: p. 468.

41. Jensen, R.T. and F. Gibril, Somatostatin receptor scintigraphy in gastrinomas. Ital J Gastroenterol Hepatol, 1999. 31(Suppl 2): p. 179-85.

42. Vinik, A.I., S. Achem-Karam, and C. Owyang, Gastrointestinal hormones in clinical medicine. In Special Topics in Endocrinology and Metabolism. Vol. 4. Edited by M.P., PP Foa. New York: Alan R. Liss, 1982, p. 93-138.

43. Vinik, A.I, L. Delbridge, R. Moattari, K. Cho, and N. Thompson, Transhepatic portal vein catheterization for localization of insulinomas: a ten-year experience. Surgery, 1991. 109: p. 1-11.

44. Vinik, A.I., W.M. Strodel, R.V. Lloyd, and N.W. Thompson, Unusual gastroenteropancreatic tumors and their hormones. Endocrine Surgery Update, Edited by N. Thompson and A.I. Vinik. 1983, New York: Grune & Stratton. p. 293.

45. Gibril, F., J.C. Reynolds, C.C. Chen, F. Yu, S.U. Goebel, J. Serrano, J.L. Doppman, and R.T. Jensen, Specificity of somatostatin receptor scintigraphy: a prospective study and effects of false-positive localizations on management in patients with gastrinomas. J Nucl Med, 1999. 40(4): p. 539-53.

46. Alexander, H.R., D.L. Fraker, J.A. Norton, D.L. Bartlett, L. Tio, S.B. Benjamin, J.L. Doppman, S.U. Goebel, J. Serrano, F. Gibril, and R.T. Jensen, Prospective study of somatostatin receptor scintigraphy and its effect on operative outcome in patients with Zollinger-Ellison syndrome. Ann Surg, 1998. 228(2): p. 228-38.

47. Thom, A.K., J.A. Norton, J.L. Doppman, et al., Prospective study of the use of intraarterial secretin injection and portal venous sampling to localize duodenal gastrinomas. Surgery, 1992. 112: p. 1002.

48. Burcharth, F., J.G. Gtage, F. Stadil, L.I. Jensen, and K. Fischermann, Localization of gastrinomas by transhepatic portal catheterization and gastrin assay. Gastroenterology, 1979. 77: p. 444.

49. Glaser, B., A.I. Vinik, A.A. Sive, et al., Evidence for estravagal cholinergic dependence of pancreatic polypeptide responses to beef ingestion in man [abstract]. Diabetes, 1979. 28: p. 414.

50. Passaro, E., Jr., Localization of pancreatic endocrine tumors by selective portal vein catheterization and radioimmunoassay. Gastroenterology, 1979. 77: p. 806.

51. Vinik, A.I, J. Glowniak, B. Glaser, et. al. Localization of gastroenteropancreatic (GEP) tumors. In Surgery 2. Endocrine Surgery. Edited by IDA Johnston, N.W. Thompson. 1983, London: Butterworth's International Medical Reviews. p. 76.

52. Glowniak, J.V., B. Shapiro, A.I. Vinik, et al. Percutaneous transhepatic venous sampling of gastrin: value in sporadic and familial islet-cell tumors of G-cell. N Engl J Med, 1982. 307: p. 293-297.

53. Deveney, C., S. Steins, and L.W. Way, Cimetidine in the treatment of Zollinger-Ellison syndrome. Am J Surg, 1983. 146: p. 116.

54. Maton, P.M., R. Vinayek, H. Frucht, et al., Long-term efficacy and safety of omeprazole in patients with Zollinger-Ellison syndrome. Gastroenterology, 1989. 97: p. 827.

55. McCarthy, D.M., Report on the U.S. experience with cimetidine in Zollinger-Ellison syndrome and other hypersecretory states. Gastroenterology, 1978. 74: p. 453.

56. Mignon, M., T. Vallot, P. Hervoir, et al., Ranitidine versus cimetidine in the management of Zollinger-Ellison syndrom. 1982: p. 169.

57. Termanini, B., F. Gibril, V.E. Sutliff, F. Yu, D.J. Venzon, and R.T. Jensen, Effect of long-term gastric acid suppressive therapy on serum vitamin B12 levels in patients with Zollinger-Ellison syndrome. Am J Med, 1998. 104(5): p. 422-30.

58. Yu, F., D.J. Venzon, J. Serrano, S.U. Goebel, J.L. Doppman, F. Gibril, and R.T. Jensen, Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome. J Clin Oncol, 1999. 17(2): p. 615-30.

59. Barreras, R.F., E. Mack, T. Goodfriend, and M. Damm, Resection of gastrinoma in the Zollinger-Ellison syndrome. Gastroenterology, 1981. 82: p. 953.

60. Deveney, C.W., K.S. Deveney, and L.W. Way, The Zollinger-Ellison syndrome - 23 years later. Ann Surg, 1978. 188: p. 384.

61. Stage, J.G. and F. Stadil, The clinical diagnosis of Zollinger-Ellison syndrome. Scand J Gastroenterol, 1979. 53: p. 79.

62. Thompson, J.C., B.G. Lewis, I. Weiner, and C. M. Townsend, Jr., The role of surgery in the Zollinger-Ellison syndrome. Ann Surg, 1983. 197: p. 594.

63. Norton, J.A., D.L. Fraker, H.R. Alexander, D.J. Venzon, J.L. Doppman, J. Serrano, S.U. Goebel, P.L. Peghini, P.K. Roy, F. Gibril, and R.T. Jensen, Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med, 1999. 341(9): p. 635-44.

64. Norton, J.A., D.T. Cromack, T.H. Shawker, et al., Intraoperative ultrasonographic localization of islet cell tumors. Ann Surg, 1988. 207: p. 160.

65. Norton, J.A., B. Sigel, A.R. Baker, et. al., Localization of an occult insulinoma by intraoperative ultrasonography. Surgery, 1985. 97: p. 381.

66. Frucht, H., J.A. Norton, F.J. London, et al., Detection of duodenal gastrinomas by operative endoscopic transillumination: a prospective study. Gastroenterology, 1990. 99: p. 1622.

67. Norton, J.A., H.R. Alexander, D.L. Fraker, D.J. Venzon, F. Gibril, and R.T. Jensen, Does the use of routine duodenotomy (DUODX) affect rate of cure, development of liver metastases, or survival in patients with Zollinger-Ellison syndrome? Ann Surg, 2004. 239(5): p. 617-26.

68. Zogakis, T.G., F. Gimbril, S.K. Libutti, J.A. Norton, D.E. White, R.T. Jensen, and H.R. Alexander, Management and outcome of patients with sporadic gastrinoma arising in the duodenum. Ann Surg, 2003. 238(1): p. 42-8.

69. Assalia, A. and M. Gagner, Laparoscopic pancreatic surgery for islet cell tumors of the pancreas. World J Surg, 2004. 28(12): p. 1239-47.

70. Gilhool, W.J., Endoscopic diagnosis and removal of duodenal wall gastrinoma. Am J Gastroenterol, 1984. 79: p. 679-83.

71. Fernandez-Cruz, L., M. Herrera, A. Saenz, et. al., Laparoscopic pancreatic surgery in patients with neuroendocrine tumors: indications and limits. Best Pract Res Clin Endocrinol Metab, 2001. 11: p. 279-83.

72. Straus, E., J.P. Raufman, S. Samues, et. al., Endoscopic cure of the Zolllinger-Ellison syndrome. Gastrointest Endosc, 1992. 38: p. 709-11.

73. Norton, J.A. and R.T. Jensen, Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome. Ann Surg, 2004. 240(5): p. 757-73.

74. van Heerden, J.A., S.L. Smith, and L.J. Miller, The management of Zollinger-Ellison syndrome in patients with multiple endocrine neoplasm Type 1. Surgery, 1986. 100: p. 971-977.

75. Norton, J.A., R.S. Warren, M.G. Kelly, M.B. Zuraek, and R.T. Jensen, Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery, 2003. 134(6): p. 1057-65.

76. Touzios, J.G., J.M. Kiely, S.C. Pitt, W.S. Rilling, E.J. Quebbeman, S.D. Wilson, and H.A. Pitt, Neuroendocrine Hepatic Metastases: Does Aggressive Management Improve Survival? Ann Surg, 2005. 241(5): p. 776-85.

77. Chamberlain, R.S., D. Canes, K.T. Brown, L. Saltz, W. Jarnagin, Y. Fong, and L. Blumgart, Hepatic Neuroendocrint Metastases: Does Intervention Alter Outcomes? J Am Coll Surg, 2000. 190(4): p. 432-45.

78. Sutliff, V.E., J.L. Doppman, F. Gibril, D.J. Venzon, F. Yu, J. Serrano, and R.T. Jensen, Growth of newly diagnosed, untreated metastatic gastrinomas and predictors of growth patterns. J Clin Oncol, 1997. 15(6): p. 2420-31.

79. Broder, L.E. and S.K. Carter, Pancreatic islet cell carcinoma: II. Results of therapy with streptozotocin in 52 patients. Ann Intern Med, 1973. 70: p. 108.

80. Friesen, S.R., Tumors of the endocrine pancreas. N Engl J Med, 1982. 306: p. 580.

81. Maton, P.N., J.D. Gardner, and R.T. Jensen, Diagnosis and management of Zollinger-Ellison syndrome. Endocrinol Metab Clin North Am, 1989. 18: p. 519.

82. Moertel, C.G., J.A. Hanley, and L.A. Johnson, Streptozotocin alone compared woth streptoxocin plus fluoracil in the treatment of advanced islet-cell carcinoma. N Engl J Med, 1980. 303: p. 1189.

83. Moertel, C.G., P.T. Lavin, and R.G. Hahn, Phase II trial of doxorubicin therapy for advanced islet cell carcinoma. Cancer Treat Rep, 1982. 66: p. 1567.

84. von Schrenck, T., J.M. Howard, J.L. Doppman, et al., Prospective study of chemotherapy in persons with metastatic gastrinoma. Gastroenterology, 1988. 94: p. 1326.

85. Wymenga, A.N., B. Eriksson, P.I. Salmela, M.B. Jacobsen, E.J. Van Cutsem, R.H. Fiasse, M.J. Valimaki, J. Renstrup, E.G. de Vries, and K.E. Oberg, Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. J Clin Oncol, 1999. 17(4): p. 1111.

86. Frank, M., K.J. Klose, M. Wied, N. Ishaque, C. Schade-Brittinger, and R. Arnold, Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors. Am J Gastroenterol, 1999. 94(5): p. 1381-7.

87. Faiss, S., P. Ulrich-Frank, M. Bohjmig, Y. Dorffel, U. Mansmann, W. Golder, E.O. Riecken, and B. Wiedenmann, Prospective, Randomized, Multicenter Trial on the Antiproliferative Effect of Lanreotide, Interferon Alfa, and Their Combination for Therapy of Metastatic Neuroendocrine Gastroenteropancreatic Tumors - The International Lantreotide and Interferon Alfa Study Group. J Clin Oncol, 2003. 21(14): p. 2689-96.

88. Shojamanesh, H., F. Gibril, A. Louie, J.V. Ojeaburu, S. Bashir, A. Abou-Saif, and R.T. Jensen, Prospective study of the antitumor effacicy of long-term octreotide treatment in patients with progressive metastatic gastrinoma. Cancer, 2002. 94(2): p. 331-43.

89. Buscombe, J.R., M.E. Caplin, and A.J. Hilson, Long-term efficacy of high-activity 111 in-pentetreotide therapy in patients with disseminated neuroendocrine tumors. J Nucl Med, 2003. 44(1): p. 1-6.

90. Abou-Saif, A., F. Gibril, J.V. Ojeaburu, S. Bashir, L.K. Entsuah, B. Asgharian, and R.T. Jensen, Prospective study of the ability of serial measurements of serum chromogranin A and gastrin to detect changes in tumor burden in patients with gastrinomas. Cancer, 2003. 98(2): p. 249-61.